Companies › Pop Test Oncology
1 active drug program in 1 registered trial: 1 Phase 1; Psychiatry; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Org-34517 (PT150) Glucocorticoid receptor antagonist | NR3C1 | Phase 1 | Alcohol Use Disorder | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06712602 | Org-34517 (PT150) | Phase 1 | Alcohol Use Disorder | Psychiatry | Jul 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.